Cabaletta Bio is a late-stage clinical biotechnology company developing curative CAR T-cell therapies for autoimmune diseases, and the company is at the inflection where the registrational data package for the lead asset rese-cel is approximately twelve months away from the planned mid-2027 readout in the RESET-Myositis trial. The fiscal second quarter produced a print that is consistent with a late-stage clinical-stage biotech: $44.4 million of research and development expense, a $51.0 million net loss, $225.1 million of cash and cash equivalents at quarter-end, and a 151.2 million weighted-average share count that is the cleanest single-sentence read on the dilution profile the company is producing. The principal question for the next four quarters is whether the company can advance the RESET-Myositis registrational trial to the mid-2027 data readout on the existing cash position, and whether the PC-free approach the company is incorporating into the RESET-MG cohort can produce a differentiated clinical profile that supports the multiple-indication expansion.
The numbers tell the story with the kind of operational detail that the late-stage clinical-stage biotech equity has been waiting for. R&D expense of $44.4 million in the quarter was 18.0 percent above the $37.6 million in the prior-year quarter, with the R&D growth driven by the registrational RESET-Myositis trial enrollment, the RESET-SSc trial initiation, and the broader RESET clinical program expansion. General and administrative expense of $7.6 million was 8.2 percent below the prior-year quarter's $8.3 million, reflecting the operating-leverage the company is producing as the R&D base expands. The H1 2026 R&D expense of $81.8 million was 22.7 percent above the prior-year period's $66.7 million, and the H1 2026 net loss of $94.5 million was 16.6 percent above the prior-year period's $81.1 million.
The cash position at quarter-end of $225.1 million in cash and cash equivalents, plus $50.6 million in short-term investments, gives a total liquidity position of $275.7 million, which is the cleanest read on the financial position the company is producing. The H1 2026 net cash used in operating activities of approximately $90 million is the structural cash burn, and the H1 2026 net cash position gives a runway of approximately 3 years at the current burn rate. The runway is comfortable for the company to advance the RESET-Myositis registrational trial to the mid-2027 data readout, and the runway is the source of the financial position the company is producing.
The question the next four quarters resolve is whether the company can advance the RESET-Myositis registrational trial to the mid-2027 data readout on the existing cash position, and whether the RESET-SSc trial initiation in 4Q26 and the PC-free approach incorporation into RESET-MG can produce a differentiated clinical profile. A 2026 fourth-quarter update that confirms the registrational RESET-Myositis trial enrollment is on track for the mid-2027 readout, and a 4Q26 update that confirms the RESET-SSc trial initiation, would confirm the company is producing the clinical and operational profile the lead-asset thesis is positioning for. A 2026 fourth-quarter update that shows the registrational RESET-Myositis trial enrollment is delayed, or a 4Q26 update that shows the RESET-SSc trial initiation is delayed, would force the market to reprice the equity for a more modest terminal value.